Allergy Therapeutics Interim Results for Six Months ended 31 December 2018. A video for investors featuring Manuel Llobet and Nick Wykeman. Allergy are listed on London's AIM stock exchange with the ticker lON:AGY.
Over the last 6 months the company has grown revenues by 10.6% to over £46m, with an operating profit of £10.7m
AGY are a revenue generating pharma business, producing vaccines for a range of allergies. In addition to their approved medicines, the company has a large R&D pipeline, with drugs in various stages of clinical trials.
In this video, the management update investors on their double digit revenue growth, as well as an increase in market share - particularly in the German market. They also update on their R&D pipeline, focusing on their phase III birch allergy trial, the phase I house dust mite trial, their first in-human trial for their peanut allergy vaccine, and the phase III for their grass allergy product.
This video was produced, edited and animated by Five Minute Pitch TV.